Omjjara
What Omjjara is used for
Omjjara is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Omjjara
- Active substance
- momelotinib
- Disease area
- Splenomegaly; Myeloproliferative Disorders
- Medicine group
- ANTINEOPLASTIC AGENTS
- Marketing authorisation holder
- GlaxoSmithKline Trading Services Limited
- Authorised in the EU since
- 2024
Official information
In the USA
Same active substance: Ojjaara
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Omjjara used for?
Omjjara is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
What is the active substance in Omjjara?
Omjjara contains momelotinib.
Who makes Omjjara?
The EU marketing authorisation holder is GlaxoSmithKline Trading Services Limited.
Is Omjjara an orphan medicine?
Yes. Omjjara is designated an orphan medicine in the EU, for a rare disease (Splenomegaly; Myeloproliferative Disorders).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU